Home » Stocks » NERV

Minerva Neurosciences, Inc. (NERV)

Stock Price: $2.33 USD 0.07 (3.10%)
Updated May 10, 2021 1:29 PM EDT - Market open
Market Cap 96.55M
Revenue (ttm) 41.18M
Net Income (ttm) 1.94M
Shares Out 40.82M
EPS (ttm) 0.05
PE Ratio 48.54
Forward PE 9.92
Dividend n/a
Dividend Yield n/a
Trading Day May 10
Last Price $2.33
Previous Close $2.26
Change ($) 0.07
Change (%) 3.10%
Day's Open 2.29
Day's Range 2.22 - 2.34
Day's Volume 195,986
52-Week Range 1.81 - 15.22

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Management to host conference call Management to host conference call

4 days ago - GlobeNewsWire

Investors need to pay close attention to Minerva Neurosciences (NERV) stock based on the movements in the options market lately.

1 month ago - Zacks Investment Research

Phase 3 open-label extension completed on schedule in patients with negative symptoms of schizophrenia and data will be available in H1 2021

2 months ago - GlobeNewsWire

LOS ANGELES, Feb. 8, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Minerva Neurosciences, Inc. ("Minerva...

3 months ago - PRNewsWire

New York, New York--(Newsfile Corp. - February 8, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of M...

3 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - February 8, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Minerva Neurosciences, Inc. (NASDAQ: NERV) betwe...

3 months ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - February 7, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Minerva Neurosci...

3 months ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - February 6, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Minerva Neurosci...

3 months ago - Newsfile Corp

NEW YORK, Feb. 5, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Minerva Neurosciences, Inc. (NASDAQ: NERV) between May 15, 2017 and...

3 months ago - PRNewsWire

New York, New York--(Newsfile Corp. - February 5, 2021) -  Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Minerva Neurosciences, Inc. ("Minerva" ...

3 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - February 4, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Minerva Neurosciences, Inc. (NASDAQ: NERV...

3 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - February 4, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of M...

3 months ago - Newsfile Corp

Boston, Massachusetts--(Newsfile Corp. - February 3, 2021) - The Thornton Law Firm announces that a class action lawsuit has been filed on behalf of investors of Minerva Neurosciences, Inc. (NASDAQ: NER...

3 months ago - Newsfile Corp

NEW YORK, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class a...

3 months ago - GlobeNewsWire

NEW YORK, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Minerva Neurosciences, Inc. (NASDAQ: NE...

3 months ago - GlobeNewsWire

New York, New York--(Newsfile Corp. - February 3, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Minerva Neurosciences, Inc. (NASDAQ: NERV...

3 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - February 3, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of M...

3 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - February 2, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Minerva Neurosciences, Inc. ("Minerva" or the "Company") (NASDAQ: NER...

3 months ago - Newsfile Corp

Click here to join the case

3 months ago - GlobeNewsWire

NEW YORK, Jan. 31, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Minerva Neurosciences, Inc. ("Minerva" or the "Company") (NASDAQ: NERV) and certain of ...

3 months ago - PRNewsWire

New York, New York--(Newsfile Corp. - January 29, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Minerva Neurosciences, Inc. (NASDAQ: NERV...

3 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - January 29, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of M...

3 months ago - Newsfile Corp

BOSTON, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Block & Leviton LLP (www.blockleviton.com), a national securities litigation firm, reminds investors that it has filed a class action lawsuit on behalf of share...

3 months ago - GlobeNewsWire

NEW YORK, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of  Minerva Neurosciences, Inc. (NASDAQ: NERV)  between May 15...

3 months ago - GlobeNewsWire

NEW YORK, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Minerva Neurosciences, Inc. (NASDAQ: NE...

3 months ago - GlobeNewsWire

New York, New York--(Newsfile Corp. - January 23, 2021) -  Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Minerva Neurosciences, Inc. (NASDAQ: NERV) between M...

3 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - January 21, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of M...

3 months ago - Newsfile Corp

NEW YORK, Jan. 21, 2021 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Minerva Neurosciences, Inc. (NASDAQ: NERV) between May 15, 2017 and Nov...

3 months ago - PRNewsWire

New York, New York--(Newsfile Corp. - January 21, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Minerva Neurosciences, Inc. (NASDAQ: NERV...

3 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - January 20, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Minerva Neurosciences, Inc. ("Minerva" or the "Company") (NASDAQ: NER...

3 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - January 20, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of M...

3 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - January 20, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Minerva Neurosciences, Inc. (NASDAQ: NERV...

3 months ago - Newsfile Corp

NEW YORK, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of  Minerva Neurosciences, Inc. (NASDAQ: NERV)  between May 15...

3 months ago - GlobeNewsWire

New York, New York--(Newsfile Corp. - January 19, 2021) -  The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of ...

3 months ago - Newsfile Corp

A slew of biopharma stocks are making big moves Tuesday on the back of clinical trial readouts as well announcements regarding M&A and tie-ups. Merus, Lilly In $1.68B Oncology Deal: Dutch-based Merus NV...

Other stocks mentioned: ACRS, CYAD, GRTS, MRUS, TENX
3 months ago - Benzinga

NEW YORK, NY / ACCESSWIRE / January 19, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. ...

Other stocks mentioned: BRY, OTGLY
3 months ago - Accesswire

NEW YORK, Jan. 18, 2021 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Minerva Neurosciences, Inc. (NASDAQ: NERV) between May 15, 2017 and...

3 months ago - GlobeNewsWire

New York, New York--(Newsfile Corp. - January 18, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of M...

3 months ago - Newsfile Corp

NEW YORK, NY / ACCESSWIRE / January 17, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a ...

Other stocks mentioned: BSX, KNDI
3 months ago - Accesswire

New York, New York--(Newsfile Corp. - January 16, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Minerva Neurosciences, Inc. ("Minerva" or the "Company") (NASDAQ: NER...

3 months ago - Newsfile Corp

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Minerva Neurosciences, Inc. (NASDAQ: NERV) between May 15, 2017 and November 30, 202...

3 months ago - Business Wire

NEW YORK, NY / ACCESSWIRE / January 14, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholder...

Other stocks mentioned: LRN, QIWI
3 months ago - Accesswire

NEW YORK, NY / ACCESSWIRE / January 13, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to partici...

Other stocks mentioned: BSX, SWI
3 months ago - Accesswire

New York, New York--(Newsfile Corp. - January 13, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of M...

3 months ago - Newsfile Corp

NEW YORK, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of  Minerva Neurosciences, Inc. (NASDAQ: NERV)  between May 15...

3 months ago - GlobeNewsWire

New York, New York--(Newsfile Corp. - January 11, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of M...

3 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - January 11, 2021) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Minerva Neurosciences, Inc. (NASDAQ: NERV) between Ma...

3 months ago - Newsfile Corp

SAN DIEGO--(BUSINESS WIRE)-- #Minervacase--The suit alleges defendants issued false statements concerning Minerva business and prospects, resulting in its stock trading at inflated prices.

3 months ago - Business Wire

NEW YORK, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of  Minerva Neurosciences, Inc. (NASDAQ: NERV)  between May 15...

4 months ago - GlobeNewsWire

NEW YORK, Jan. 6, 2021 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Minerva Neurosciences, Inc. (NASDAQ: NERV) between May 15, 2017 and Nove...

4 months ago - PRNewsWire

About NERV

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, a compound in Phase III clinical trial for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma C... [Read more...]

Industry
Biotechnology
IPO Date
Jul 1, 2014
CEO
Remy Luthringer
Employees
11
Stock Exchange
NASDAQ
Ticker Symbol
NERV
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for NERV stock is "Buy." The 12-month stock price forecast is 7.00, which is an increase of 200.43% from the latest price.

Price Target
$7.00
(200.43% upside)
Analyst Consensus: Buy